Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.58 |
| ▸ | CES2 | O00748 | 2/20 | 0.54 |
| ▸ | CES1 | P23141 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | CETP | P11597 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26445070 | 1.00 | KMT2A (0.66) | KMT2AMEN1EPHX2CES2CES1 | |
| SCHEMBL5142795 | 1.00 | KMT2A (0.66) | KMT2AMEN1EPHX2CES2CES1 | |
| SCHEMBL547836 | 1.00 | KMT2A (0.66) | KMT2AMEN1EPHX2CES2CES1 | |
| SCHEMBL28089503 | 1.00 | KMT2A (0.66) | KMT2AMEN1EPHX2CES2CES1 | |
| SCHEMBL7038549 | 1.00 | KMT2A (0.66) | KMT2AMEN1EPHX2CES2CES1 | |
| SCHEMBL28382194 | 1.00 | KMT2A (0.66) | KMT2AMEN1EPHX2CES2CES1 | |
| SCHEMBL8084828 | 1.00 | KMT2A (0.66) | KMT2AMEN1EPHX2CES2CES1 | |
| SCHEMBL9060468 | 1.00 | KMT2A (0.66) | KMT2AMEN1EPHX2CES2CES1 | |
| SCHEMBL7036521 | 1.00 | KMT2A (0.66) | KMT2AMEN1EPHX2CES2CES1 | |
| SCHEMBL8510522 | 1.00 | KMT2A (0.66) | KMT2AMEN1EPHX2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205143-A1 | ADDITIVE FOR SUNSCREENS | SYMRISE AG (DE) | 2025-06-26 | — | — | US | disclosed |
| US-20250143988-A1 | COMPOSTITION WITH STABILIZED TASTE AND ODOR | SYMRISE AG (DE) | 2025-05-08 | — | — | US | disclosed |
| US-12226501-B2 | Composition with stabilized taste and odor | SYMRISE AG (DE) | 2025-02-18 | — | — | US | disclosed |
| CN-110747038-A | Suspension preparation method | 上海大学 | 2020-02-04 | — | — | CN | disclosed |
| EP-1286786-A2 | SPREADABLE ADHESIVE COMPOSITIONS AND APPLICATORS FOR USE THEREWITH | Loctite (R & D) Limited (IE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001091915-A2 | SPREADABLE ADHESIVE COMPOSITIONS AND APPLICATORS FOR USE THEREWITH | LOCTITE (R & D) LIMITED (IE) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001092430-A1 | SEMI-SOLID COMPOSITIONS FOR REMOVING CURED PRODUCT | LOCTITE (R & D) LIMITED (IE) | 2001-12-06 | — | — | WO | disclosed |
| US-4212862-A | FOR PLANT DISEASES | BLIZNJUK ALEXANDR N | 1980-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12226501-B2 | Composition with stabilized taste and odor | TAS2R13, TAS2R16, TAS2R20 | KMT2A 3775/4885MEN1 530/4885EPHX2 1048/4885 |
| US-20250205143-A1 | ADDITIVE FOR SUNSCREENS | CUTA, BRCA1, SUN2 | KMT2A 1019/4885MEN1 909/4885EPHX2 303/4885 |
| US-20250143988-A1 | COMPOSTITION WITH STABILIZED TASTE AND ODOR | TAS2R16, TAS2R8, FFAR2 | KMT2A 3776/4885MEN1 672/4885EPHX2 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.